A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes

American Journal of Tropical Medicine and Hygiene

Volumn 65, Issue 5, 2001, Pages 414-419

  Troyer, J M ^a   Hanley, K A ^a   Whitehead, S S ^a   Strickman, D ^a   Karron, R A ^a   Durbin, A P ^a   Murphy, B R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

3' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENGUE VIRUS; FEMALE; GENE DELETION; HUMAN; IMMUNIZATION; INOCULATION; MALE; MIDGUT; MOSQUITO; NONHUMAN; PHASE 1 CLINICAL TRIAL; SALIVARY GLAND; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0035215425     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2001.65.414     Document Type: Article

References (35)

1. Flaviviruses
2. Research on dengue during World War II
3. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia
4. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity
5. Impact of dengue virus infection and its control
6. Dengue and dengue hemorrhagic fever
7. Impact of dengue/dengue hemorrhagic fever on the developing world
8. Outbreak of poliomyelitis - Dominican Republic and Haiti, 2000
9. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland
10. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes
11. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice
12. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine
13. Attenuation of the Langat tick-borne flavivirus by chimerization with mosquito-borne flavivirus dengue type 4
14. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
15. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates
16. Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties
17. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys
18. Attenuation and immunogenicity in humans of a live dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region
19. Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus
20. Studies on the feeding response of mosquitoes to nutritive solutions in a new membrane feeder
21. Effect of size and geographic origin of Aedes aegypti on oral infection with dengue-2 virus
22. A simple method of estimating fifty percent endpoints
23. Evaluation of Toxorhynchites splendens (Diptera:Culicidae) as a bioassay host for dengue viruses
24. The use of mosquitoes to detect and propagate dengue viruses
25. Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses
26. Quantity of dengue virus required to infect rhesus monkeys
27. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3
28. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti
29. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: A possible marker of human attenuation
30. Dengue-2 vaccine: Infection of Aedes aegypti mosquitoes by feeding on viremic recipients
31. Quantitative genetics of vector competence for dengue-2 virus in Aedes aegypti
32. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti
33. Factors influencing the transmission of dengue viruses
34. Laboratory and diagnosis of dengue virus infections
35. Invited commentary: Dengue lessons from Cuba